THIS IS BIG potential news for the CRC, Lung and Pancreatic cancer worlds. Just announced: the initiation of a KRAS-mutant directed personalized cellular therapy Phase 1 clinical trial for SOME segments of the KRAS-mutant CRC, Lung and pancreatic cancer patient populations - it will depend on the exact mutation and your HLA type. They have not announced the exact mutations or required HLA types yet - but will soon. I will post as soon as available.
The "drugs" will be living immune cells.
It is essentially an effort to commercialize in a more logistically efficient way the NIH TIL trial but limited to only certain slices of patients with certain KRAS-mutations and HLA-types
Expect a lot more info to be coming out soon. From a technology point of view, this is BIG. I'll be writing a science blog about it soon.
I'll announce (and explain) more details as they come out - this is just an exciting teaser press release, but they say trial will start in 2016.
http://www.businesswire.com/news/home/2 ... 006760/en/
Welcome to the future!
-DK37